Hyposexual is a broad descriptor for unusually low or absent sexual desire, interest, or drive. In clinical settings, the more precise term is hypoactive sexual desire disorder (HSDD), a diagnosis applied when persistently low desire causes personal distress. The word itself is straightforward: “hypo” means under or below, so hyposexual simply means below-typical sexual interest. But the science behind why some people experience this, how it differs from asexuality, and what can be done about it is more layered than the label suggests.
What the Term Covers in Practice
You might encounter “hyposexual” used casually to describe anyone whose sex drive feels lower than they or a partner would expect. Clinically, though, the concept maps onto specific diagnostic categories. HSDD has historically been the main one: a persistent deficit in sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The most recent edition of the major psychiatric diagnostic manual merged desire and arousal problems in women into a single category called female sexual interest/arousal disorder, though many sexual medicine organizations pushed back on that merger, arguing that desire and arousal are distinct processes that should be diagnosed separately.
Professional bodies specializing in sexual medicine have published their own guidelines that diverge from psychiatric classifications, recommending the separation of desire and arousal disorders, elaborating on different subtypes of arousal problems, and broadening definitions of sexual pain conditions.1Oxford Academic (Sexual Medicine Reviews). The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD The takeaway for someone trying to understand their own experience is that “low desire” is not one monolithic thing. It can be lifelong or acquired, situational or generalized, and the cause might be hormonal, psychological, relational, medication-related, or some combination.
Hyposexual Versus Asexual
One of the most important distinctions in this space is between someone who has low desire and is distressed about it, and someone who simply does not experience sexual attraction and is fine with that. Asexuality is increasingly understood as a sexual orientation rather than a disorder. Research comparing asexual individuals with people diagnosed with HSDD has found meaningful differences: people who scored high on an asexuality inventory were more likely to have never engaged in sexual intercourse, fantasies, or kissing, and they reported less sex-related distress than those with HSDD.2PubMed. Asexuality: an extreme variant of sexual desire disorder? In other words, the absence of desire itself is not the defining problem in HSDD. The distress is.
Brain imaging work reinforces this distinction. When researchers compared how asexual women and women diagnosed with sexual interest/arousal disorder responded to sexual images, the two groups showed different patterns of initial attention to sexual content, suggesting the underlying neurology is not the same.3PubMed Central. Asexuality vs. sexual interest/arousal disorder: Examining group differences in initial attention to sexual stimuli A review of available evidence concluded that asexuality does not meet the criteria for a psychiatric condition or a disorder of sexual desire, and that it likely qualifies as a distinct sexual orientation.4PubMed. Asexuality: Sexual Orientation, Paraphilia, Sexual Dysfunction, or None of the Above? If you are not bothered by a lack of sexual interest, you probably do not have a disorder. If you are bothered, that is when the clinical picture becomes relevant.
What Brain Imaging Reveals
Neuroimaging studies have started to map what is different in the brains of people with low sexual desire, and the picture is more interesting than a simple “less activity” story. In one study, women without HSDD showed greater activation in brain regions involved in processing erotic stimuli, including areas tied to attention, sensory integration, and memory. But women with HSDD did not just show less activation in those areas. They also showed extra activation in regions associated with higher-order social and cognitive functions, which researchers interpreted as possibly reflecting different subjective or social interpretations of sexual content.5PubMed. Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study In plain terms, the brain of someone with low desire may not just be “tuning out” sexual cues; it may be actively processing them through a different, more analytical or self-conscious lens.
A separate pilot study confirmed a similar pattern: women with normal sexual function showed significantly greater activation in the thalamus, insula, and several other regions when viewing erotic material, while women with HSDD showed greater activation in the medial frontal gyrus, an area linked to self-referential thinking and decision-making.6PubMed Central. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study The emerging theme is that hyposexuality may involve not just dampened arousal circuitry but also a kind of cognitive override, where the brain’s evaluative centers step in more forcefully.
There are also sex differences in how low desire manifests neurologically. A 2024 study found that when men and women with HSDD watched sexual videos, women showed significantly greater activation than men in the amygdala, hypothalamus, and thalamus, key nodes in the brain’s sexual response network.7Scientific Reports. Women and men with distressing low sexual desire exhibit sexually dimorphic brain processing This suggests that the neurobiological underpinnings of low desire are not identical across sexes, which matters for treatment development.
Underlying these findings is a broader theoretical framework: the dual control model of sexual response, which proposes that arousal depends on the balance between excitatory and inhibitory systems in the brain, and that people differ in their baseline propensity for each.8PubMed. The Dual Control Model of Sexual Response: A Scoping Review, 2009-2022 Someone with a naturally high inhibitory set point might experience lower desire even without any specific pathology. This framework helps explain why hyposexuality exists on a spectrum and why two people with similar hormone levels might have very different levels of desire.
The Hormone Connection
Hormones play a role in sexual desire, but the relationship is less straightforward than popular culture suggests. It is not as simple as “low testosterone equals low desire.” In women, free testosterone and androstenedione have been correlated with sexual desire in some age groups, particularly in younger women not using hormonal contraception, where total testosterone, free testosterone, androstenedione, and DHEAS all showed associations with desire.9The Journal of Sexual Medicine. Is There a Correlation Between Androgens and Sexual Desire in Women? But these are correlations, not proof of causation, and many women with low androgen levels have perfectly normal desire while some with higher levels do not.
Life transitions create natural hormonal shifts that can drag desire down. During the postpartum period, women experience broad neuroendocrine changes. Brain imaging work has shown that postpartum women have lower right amygdala responsiveness to arousing images compared to women who have never given birth, and this decreased responsiveness extends beyond sexual stimuli to include infant and neutral images alike, suggesting a generalized dampening of arousal rather than a specifically sexual one.10PubMed Central. Lower sexual interest in postpartum women: relationship to amygdala activation and intranasal oxytocin Menopause brings its own hormonal upheaval, with declining estrogen and testosterone contributing to changes in desire for many women.11The Open Biochemistry Journal. A Detailed Biological Approach on Hormonal Imbalance Causing Depression in Critical Periods (Postpartum, Postmenopausal and Perimenopausal Depression) in Adult Women
Medical conditions can also intersect with hormonal and vascular pathways that affect desire and arousal. The sexual response in women depends partly on blood flow to genital tissues, and conditions that damage endothelial function, like diabetes, may contribute to dysfunction. That said, the evidence connecting specific cardiometabolic conditions to female sexual dysfunction is still mixed. While the prevalence of sexual dysfunction appears higher in women with diabetes, a definitive cause-and-effect link has not been established, and data on the effects of obesity, high cholesterol, and high blood pressure on women’s sexual function remain limited and sometimes contradictory.12Oxford Academic (Sexual Medicine Reviews). Cardiometabolic Risk and Female Sexuality—Part I. Risk Factors and Potential Pathophysiological Underpinnings for Female Vasculogenic Sexual Dysfunction Syndromes
Medications That Can Suppress Desire
Some of the most common causes of acquired low desire are sitting in people’s medicine cabinets. Antidepressants, particularly SSRIs and SNRIs, are well-known culprits for sexual side effects including reduced desire, difficulty with arousal, and trouble reaching orgasm. Certain other antidepressants, including bupropion and mirtazapine, have been associated with fewer sexual side effects, and some of these alternatives have even been used to treat the sexual dysfunction caused by SSRIs and SNRIs.13PubMed. Antidepressants and sexual dysfunction: mechanisms and clinical implications If you started an antidepressant and noticed your desire evaporate, it is worth discussing alternatives with your prescriber rather than assuming that is just how life is now.
Hormonal contraceptives are another significant contributor, and this one catches many people by surprise. A systematic review and meta-analysis found that combined oral contraceptive use significantly decreased total testosterone levels and reduced free testosterone by about 61% on average, while substantially increasing sex hormone-binding globulin, the protein that binds up circulating testosterone and makes it unavailable.14PubMed Central. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis Since free testosterone is one of the androgens linked to desire, this hormonal shift can meaningfully affect sex drive in some users. Research in women with sexual dysfunction found that oral contraceptive use was associated with decreased androgen production and increased sex hormone-binding globulin.15The Journal of Sexual Medicine. Impact of Oral Contraceptives on Sex Hormone‐Binding Globulin and Androgen Levels: A Retrospective Study in Women with Sexual Dysfunction Not every person on hormonal contraception will notice a change, but for those who do, the connection is physiologically real and well-documented.
Stress, the Body’s Braking System
Chronic stress is perhaps the most universal desire-dampener, and there is real biology behind the cliché. The body’s stress-response system and its sexual-response system are in a kind of tug-of-war. Research has found that women whose cortisol increased in response to watching a sexual film reported lower desire, lower arousal, and lower sexual satisfaction than women whose cortisol decreased.16PubMed Central. Cortisol, Sexual Arousal, and Affect in Response to Sexual Stimuli In your body’s priority system, responding to perceived threats outranks reproduction.
This goes deeper than momentary stress. Women diagnosed with HSDD have been shown to have multiple markers of a chronically disrupted stress-response system, including lower morning cortisol and DHEA levels and a flatter daily cortisol curve compared to women without the diagnosis.17PubMed Central. Dehydroepiandrosterone and cortisol as markers of HPA axis dysregulation in women with low sexual desire The stress system and the hormonal pathways that support desire share overlapping biology, so chronic stress does not just distract you from sex; it may physiologically remodel the systems that generate desire in the first place.
Relationship dynamics add another psychological layer. Desire discrepancy, where partners want sex at different frequencies, is one of the most common sexual complaints in couples. A study of over 200 participants found that people used a wide variety of strategies to cope, including disengagement, communication, solo activity, partner-focused activities, and simply having sex anyway. Strategies that involved both partners were associated with higher sexual and relationship satisfaction compared to individual strategies.18PubMed Central. Strategies for Mitigating Sexual Desire Discrepancy in Relationships Societal pressures compound the problem: cultural norms around sexuality, body image concerns, and unrealistic media portrayals of sex can all contribute to feelings of inadequacy or shame that further suppress desire.19PubMed Central. Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment
Pharmacological Options
Two drugs have been approved specifically for low sexual desire in premenopausal women, and each works through a completely different mechanism. Flibanserin, taken as a daily pill, acts primarily as an agonist at one type of serotonin receptor and an antagonist at another, essentially tweaking the balance of neurotransmitters involved in desire.20The Journal of Sexual Medicine. Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder It was sometimes called “female Viagra” in the media, but that comparison is misleading. Viagra addresses blood flow for erections; flibanserin targets brain chemistry related to desire. The effect size is modest, and it requires daily use along with alcohol avoidance, which limits its appeal for many people.
Bremelanotide takes a different route entirely. It is a synthetic peptide that binds to melanocortin receptors in the brain thought to be involved in sexual response, and it is self-injected before anticipated sexual activity rather than taken daily.21PubMed. Bremelanotide: First Approval Interestingly, the exact mechanism is still debated. Animal research found that bremelanotide did not increase sex-related reward behaviors in hamsters and did not affect melanocortin-4 receptor expression, raising questions about whether the drug works through the pathway researchers initially assumed.22The Journal of Sexual Medicine. Examining the Neuroanatomical Basis of Bremelanotide, a Drug for Low Sexual Desire in Women Nausea is a common side effect, which can be a dealbreaker.
Testosterone therapy is a third pharmacological avenue, used off-label for women since no testosterone product is specifically approved for female use in most countries. A global consensus position statement found that testosterone at doses approximating normal premenopausal levels produced a beneficial effect on sexual function, including an average of about one additional satisfying sexual event per month beyond placebo, along with improvements in desire, arousal, orgasm, and sexual responsiveness.23PubMed Central. Global Consensus Position Statement on the Use of Testosterone Therapy for Women One extra satisfying sexual event per month may sound underwhelming on paper, but for someone experiencing significant distress over absent desire, it can represent a meaningful quality-of-life change. A position statement from the Brazilian Society of Endocrinology and Metabolism echoed the positive effect on desire but noted a small magnitude of effect and insufficient long-term safety data to make a broad recommendation.24PubMed Central. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism When testosterone is used, transdermal formulations like creams, gels, or patches are preferred because they allow dosing to be titrated to physiological levels. Users are typically advised about the risk of transferring testosterone to others through skin contact.25PubMed. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review
Non-Drug Approaches That Show Promise
Psychological treatments have a growing evidence base, and for many people they may be more appropriate than medication, especially when the causes of low desire are relational, stress-related, or connected to body image and self-consciousness. Mindfulness-based therapy, in particular, has shown strong results. A study of women seeking treatment for low desire and arousal found that four group sessions incorporating mindfulness meditation, cognitive therapy, and education significantly improved sexual desire, arousal, lubrication, satisfaction, and overall sexual functioning compared to a control group.26PubMed. Group mindfulness-based therapy significantly improves sexual desire in women The logic makes sense in light of the brain imaging findings: if part of the problem is excessive cognitive interference during sexual situations, training the brain to stay present rather than evaluating and judging may directly counteract that pattern.
Traditional cognitive behavioral therapy also helps. A randomized study comparing video-based mindfulness-based cognitive therapy with video-based traditional CBT found that women in both groups showed increased sexual functioning and decreased sexual distress, with improvements in desire, arousal, orgasm, and satisfaction.27The Journal of Sexual Medicine. A Randomized Study Comparing Video-Based Mindfulness-Based Cognitive Therapy With Video-Based Traditional Cognitive Behavioral Therapy in a Sample of Women Struggling to Achieve Orgasm Researchers are also testing internet-delivered versions of both approaches, which could dramatically improve access for people who cannot attend in-person sessions or prefer privacy.28PubMed Central. Psychological Treatment of Low Sexual Desire in Women: Protocol for a Randomized, Waitlist-Controlled Trial of Internet-Based Cognitive Behavioral and Mindfulness-Based Treatments
Pelvic floor muscle training is another option that might seem unexpected for a desire problem. A systematic review and meta-analysis found that pelvic floor training improved arousal, orgasm, satisfaction, pain during sex, and overall sexual functioning scores.29PubMed. Pelvic floor muscle training as treatment for female sexual dysfunction: a systematic review and meta-analysis The connection is partly indirect: if sex is physically uncomfortable or unsatisfying because of weak or dysfunctional pelvic muscles, desire naturally erodes. Addressing the physical experience of sex can create a positive feedback loop that supports desire.
When Low Desire Is Situational
One nuance that gets lost in clinical discussions is the difference between generalized and situational low desire. Generalized means you have reduced interest across all contexts, partners, and types of stimulation. Situational means you lack desire in specific circumstances but not others. Someone who has no interest in sex with a long-term partner but still experiences desire in fantasy, while reading erotica, or in the early months of a new relationship does not have the same condition as someone who never experiences desire at all. Situational low desire often points toward relationship dynamics, familiarity effects, or specific psychological triggers rather than neurological or hormonal causes.
This distinction matters for treatment. A person with situational desire loss is unlikely to benefit much from flibanserin or testosterone because the biological machinery of desire is intact; the issue is contextual. Couples therapy, sensate focus exercises, or individual work on the relational and psychological barriers tends to be more productive. Conversely, someone with generalized, lifelong low desire and no identifiable psychosocial cause may be a better candidate for pharmacological or hormonal intervention. In practice, most clinicians look for a combination approach, and the best outcomes usually come from addressing multiple contributing factors rather than treating low desire as a single-cause problem.
How Low Desire Research Skews Toward Women
If you have been reading carefully, you may have noticed that the vast majority of the research cited above focuses on women. This is not accidental. The clinical study of low desire has been overwhelmingly female-focused, partly because HSDD was historically framed as a women’s health issue and partly because pharmaceutical development targeted women. Men’s low desire is studied far less, despite the fact that it is not rare. Male HSDD exists as a recognized diagnosis, and the causes overlap with those in women: stress, depression, medication side effects, low testosterone, relationship problems, and chronic illness all play roles. But research funding, clinical trials, and approved treatments have disproportionately addressed the female experience.
This disparity means that men with low desire often face an additional barrier: the assumption that something must be seriously wrong if a man does not want sex, given cultural expectations around male sexuality. The brain imaging study that found women and men with HSDD process sexual content differently underscores why findings from women cannot simply be extrapolated to men.30Scientific Reports. Women and men with distressing low sexual desire exhibit sexually dimorphic brain processing The neurobiology is not identical, which means treatment approaches may need to differ as well. Testosterone supplementation for men with documented low testosterone and low desire has a stronger evidence base than most other interventions, but for men with normal testosterone, the treatment landscape is thin. No drug equivalent to flibanserin or bremelanotide has been approved for men.